Skip to main content Skip to section navigation Skip to footer
CohBar, Inc.
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Programs & Pipelines
    • Overview
    • Our Approach
    • CB5138-3
    • CB4211
    • CB5064 Analogs
    • Posters & White Papers
  • Patient Resources
    • Overview
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Partners
  • Careers
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
Oct 28, 2021 8:45am EDT

CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants

Oct 27, 2021 4:01pm EDT

CohBar Announces Proposed Public Offering of Common Stock and Warrants

Oct 13, 2021 9:00am EDT

CohBar Announces CB4211 Phase 1a/1b Results Selected for Late Breaker Presentation at The Liver MeetingĀ® 2021

Oct 05, 2021 9:00am EDT

CohBar to Present at H.C. Wainwright 5th Annual NASH Investor Conference

Sep 15, 2021 9:00am EDT

CohBar Appoints Joanne Yun, Ph.D. to Its Board of Directors

Sep 08, 2021 9:00am EDT

CohBar Granted U.S. Patent Covering CB4211 Compositions and Use for Treating Nonalcoholic Steatohepatitis (NASH)

Sep 02, 2021 4:05pm EDT

CohBar to Present at Upcoming Investor Conferences

Aug 16, 2021 9:00am EDT

CohBar Appoints Carol Nast to Its Board of Directors

Aug 10, 2021 4:04pm EDT

CohBar Reports Second Quarter 2021Ā Financial Results and Provides Business Update

Aug 10, 2021 4:02pm EDT

CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …17
  • arrow_forward
©2022 CohBar, Inc. All Rights Reserved.
Privacy Policy Sitemap Terms of Use